Read by QxMD icon Read

Non-alcoholic fatty liver

Kannan Sridharan, Gowri Sivaramakrishnan, Reginald Paul Sequeira, Abdelaziz Elamin
AIM: Several drugs have been used for treating non-alcoholic fatty liver disease (NAFLD). The present study is a network meta-analysis of such drugs. DESIGN, SETTING AND PATIENTS: Randomised clinical trials comparing drug interventions in patients with NAFLD were analysed. OR and weighted mean difference (95 % CI) were the effect estimates for categorical and numerical outcomes, respectively. Random-effects model was used to generate pooled estimates. Surface under the cumulative ranking curve was used to rank the treatments...
October 19, 2018: Postgraduate Medical Journal
Dandan Wang, Lingling Lao, Xiaohong Pang, Qian Qiao, Lijun Pang, Zhongwen Feng, Facheng Bai, Xuemei Sun, Xing Lin, Jinbin Wei
Endoplasmic reticulum stress (ERS) is induced by accumulation of misfolded proteins, playing a pivotal role during the processes of non-alcoholic fatty liver disease (NAFLD). The present study was to investigate the effect of Asiatic acid from Potentilla chinensis (AAPC) on liver cell lipid metabolism, exploring the underlying mechanism of AAPC against NAFLD. In vivo, the animal NAFLD model was induced by feeding rats with high fat diet (HFD) for 18 weeks, and meanwhile the rats were treated with AAPC from weeks 8 to 18; In vitro experiment, the effect of AAPC on dyslipidemia induced by oleic acid (OA) in hepatic cells (HepG2) was evaluated...
October 16, 2018: International Immunopharmacology
Zdenka Gasparova, Pavol Janega, Peter Weismann, Hisham El Falougy, Barbara Tyukos Kaprinay, Boris Liptak, Dominika Michalikova, Ruzena Sotnikova
Fat-rich diet (FRD) triggers health complications like hypertension, dyslipidemia, hyperglycemia, insulin resistance and non-alcoholic fatty liver disease, known as the risk factors of metabolic syndrome (MetS), which may result in neurological deficits. The impact of MetS on neuronal functions and brain morphology are poorly understood. We induced MetS-like conditions by exposing hypertriacylglycerolemic (HTG) rats to FRD for eight weeks with the aim to study possible neurological dysfunctions. HTG-FRD rats were compared to HTG rats and Wistar rats on standard diet...
October 19, 2018: General Physiology and Biophysics
H Borgeraas, L H Barstad, R Størdal Lund, J M Fredheim, J K Hertel, J Hjelmesæth
Objectives: Early obesity onset is a risk factor for specific comorbidities in adulthood, but whether this relationship is present in men and women with severe obesity is unknown. This study aimed to examine whether obesity onset in childhood or adolescence, as compared with adulthood, is associated with higher odds of comorbidities in men and women with severe obesity. Methods: A cross-sectional study of treatment-seeking men and women with severe obesity attending a tertiary care centre in Norway, from 2006 to 2017, was performed...
October 2018: Obesity Science & Practice
Stephanie R Wesolowski, Christopher M Mulligan, Rachel C Janssen, Peter R Baker, Bryan C Bergman, Angelo D'Alessandro, Travis Nemkov, Kenneth N Maclean, Hua Jiang, Tyler A Dean, Diana L Takahashi, Paul Kievit, Carrie E McCurdy, Kjersti M Aagaard, Jacob E Friedman
OBJECTIVE: Non-alcoholic fatty liver disease (NAFLD) risk begins in utero in offspring of obese mothers. A critical unmet need in this field is to understand the pathways and biomarkers underlying fetal hepatic lipotoxicity and whether maternal dietary intervention during pregnancy is an effective countermeasure. METHODS: We utilized a well-established non-human primate model of chronic, maternal, Western-style diet induced obesity (OB-WSD) compared with mothers on a healthy control diet (CON) or a subset of OB-WSD mothers switched to the CON diet (diet reversal; OB-DR) prior to and for the duration of the next pregnancy...
September 28, 2018: Molecular Metabolism
Cameron T Locklear, Pegah Golabi, Lynn Gerber, Zobair M Younossi
BACKGROUND: Various etiologies of chronic liver disease often result in cirrhosis. Beside obvious liver-related complications, cirrhosis also leads to loss of muscle mass and decreased exercise capacity. In this study, our aim was to conduct a systematic review of literature to investigate the efficacy of exercise interventions in patients with cirrhosis. METHOD: PubMed was used to perform the literature search. The mesh terms used were the following: (liver (and) cirrhosis (and) exercise or (exercise therapy))...
October 2018: Medicine (Baltimore)
Mona Munteanu, Raluca Pais, Valentina Peta, Olivier Deckmyn, Joseph Moussalli, Yen Ngo, Marika Rudler, Pascal Lebray, Frederic Charlotte, Vincent Thibault, Olivier Lucidarme, An Ngo, Françoise Imbert-Bismut, Chantal Housset, Dominique Thabut, Vlad Ratziu, Thierry Poynard
BACKGROUND: Although the FibroTest has been validated as a biomarker to determine the stage of fibrosis in non-alcoholic fatty liver disease (NAFLD) with results similar to those in chronic hepatitis C (CHC), B (CHB), and alcoholic liver disease (ALD), it has not yet been confirmed for the prediction of liver-related death. AIM: To validate the 10-year prognostic value of FibroTest in NAFLD for the prediction of liver-related death. METHOD: Patients in the prospective FibroFrance cohort who underwent a FibroTest between 1997 and 2012 were pre-included...
October 17, 2018: Alimentary Pharmacology & Therapeutics
Shefaa AlAsfoor, Theresa V Rohm, Angela J T Bosch, Thomas Dervos, Diego Calabrese, Matthias S Matter, Achim Weber, Claudia Cavelti-Weder
Macrophages have been recognized as key players in non-alcoholic fatty liver disease (NAFLD). Our aim was to assess whether pharmacological attenuation of macrophages can be achieved by imatinib, an anti-leukemia drug with known anti-inflammatory and anti-diabetic properties, and how this impacts on NAFLD. We analyzed the pro- and anti-inflammatory gene expression of murine macrophages and human monocytes in vitro in the presence or absence of imatinib. In a time-resolved study, we characterized metabolic disease manifestations such as hepatic steatosis, systemic and adipose tissue inflammation as well as lipid and glucose metabolism in obese mice at one and three months of imatinib treatment...
October 17, 2018: Scientific Reports
Huanhuan Yang, Deming Li, Xiaochao Song, Fang Liu, Xinjing Wang, Qinghua Ma, Xi Zhang, Xinli Li
BACKGROUND: Epidemiological evidence suggests sex difference in serum uric acid (SUA) and alanine aminotransferase (ALT) might be a potential explanation for the gender difference in prevalence of non-alcoholic fatty liver disease (NAFLD). However, few epidemiology data in China have tested this hypothesis. METHODS: We conducted a cross-sectional study to assess the joint associations between SUA and serum ALT with NAFLD among elderly Chinese men and women. RESULTS: Among 7569 participants with a mean age of 59...
October 17, 2018: Journal of Translational Medicine
Natalie Chaves Cayuela, Gabrielly Pascoa Negreti, Roberto Rasslan, Marcia Kiyomi Koike, Edna Frasson de Souza Montero
PURPOSE: To evaluate the oxidative stress, resulting from ischemia and hepatic reperfusion, in mice with non-alcoholic hepatic steatosis and steatohepatitis. METHODS: C57BL/6 male mice were used. Part of them were ob/ob mice, and the other part was fed with standard or MCD diets - this last used to develop steatohepatitis. The animals - MCD-I/R, ob/ob-I/R and I/R groups - were submitted to 30 minutes of partial hepatic ischemia, followed by reperfusion for 24 hours...
September 2018: Acta Cirúrgica Brasileira
Yin Hua Zhang, De Qiang Ma, De Ping Ding, Juan Li, Lin Li Chen, Kang Jian Ao, You You Tian
PURPOSE: To explore the influence of S100 calcium binding protein A4 (S100A4) knockout (KO) on methionine-choline-deficient (MCD) diet-induced non-alcoholic fatty liver disease (NAFLD) in mice. MATERIALS AND METHODS: S100A4 KO mice (n=20) and their wild-type (WT) counterparts (n=20) were randomly divided into KO/MCD, Ko/methionine-choline-sufficient (MCS), WT/MCD, and WT/MCS groups. After 8 weeks of feeding, blood lipid and liver function-related indexes were measured...
November 2018: Yonsei Medical Journal
Zhongyong Zhang, Yueying Qi, Wubao Kong, Qianqian Jin, Xiaoyun Wang, Yanfang Dong, Yuansong Wang, Huajun Li
BACKGROUND The aim of this study was to investigate the efficacy and clinical value of liraglutide for the treatment of patients with diabetes mellitus (DM) complicated by non-alcoholic fatty liver disease (NAFLD). MATERIAL AND METHODS Patients with DM complicated by NAFLD (n=835) were enrolled. Patients were divided into 2 groups: 424 patients were included in the liraglutide group and 411 patients were included in the conventional drug group. Venous blood was collected to test blood glucose levels, blood lipid levels, and liver function...
October 16, 2018: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
Christiana Lucas, Georgia Lucas, Nicholas Lucas, Joanna Krzowska-Firych, Krzysztof Tomasiewicz
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the Western world. Ongoing research has furthered our understanding of NAFLD, the nature of progression of this disease, and its impact on morbidity and mortality. An active form of NAFLD is non-alcoholic steatohepatitis (NASH); it is the most severe subtype, without any current recommended therapies, according to the European Medicines Agency. The development of new therapies presents challenges, notably due to the slow progression of NASH and the clinically relevant endpoints...
September 2018: Clinical and Experimental Hepatology
Krzysztof Tomasiewicz, Robert Flisiak, Waldemar Halota, Jerzy Jaroszewicz, Dariusz Lebensztejn, Wojciech Lisik, Piotr Małkowski, Małgorzata Pawłowska, Anna Piekarska, Krzysztof Simon, Olga Tronina
The Polish Group of Experts for Non-Alcoholic Fatty Liver Disease (PGE-NAFLD) is a multidisciplinary team of hepatology experts established by the Polish Association for the Study of Liver and the Polish Society of Epidemiology and Infectious Diseases. The recommendations for the management of non-alcoholic fatty liver disease have been developed by a group of experts in hepatology under the auspices of the Polish Association for the Study of Liver and the Polish Society of Epidemiology and Infectious Diseases...
September 2018: Clinical and Experimental Hepatology
Guozhen Cui, Robert C Martin, Xingkai Liu, Qianqian Zheng, Harshul Pandit, Ping Zhang, Wei Li, Yan Li
Background: Non-alcoholic fatty liver disease (NAFLD) covers a spectrum of lesions ranging from steatosis to a complex pattern, nonalcoholic steatohepatitis (NASH). Ultrasonography provides important information on hepatic architecture for steatosis. NASH patients have an increased risk of hepatocellular carcinoma (HCC). Early detection of NASH is critical for clinicians to advise on necessary treatments to prevent the onset of HCC. Methods: We established a NASH-HCC mouse model using diethylnitrosamine as a carcinogen to induce HCC and a high-fat diet to induce metabolic disorders...
2018: Nutrition & Metabolism
Mitchell Bijnen, Nicky Beelen, Suzan Wetzels, José van de Gaar, Maria Vroomen, Erwin Wijnands, Jean L Scheijen, Marjo P H van de Waarenburg, Marion J Gijbels, Jack P Cleutjens, Erik A L Biessen, Coen D A Stehouwer, Casper G Schalkwijk, Kristiaan Wouters
Non-alcoholic fatty liver disease is a spectrum of liver diseases ranging from steatosis only to non-alcoholic steatohepatitis (NASH). The latter is characterized by hepatic inflammation, which increases the risk of cardiovascular disease. It is poorly understood which factors contribute to the onset of hepatic inflammation characterizing the progression from steatosis to NASH. Previously, we demonstrated increased advanced glycation endproducts (AGEs) in the livers of NASH patients. We hypothesise that AGEs play a key role in NASH development by activating their proinflammatory receptor, RAGE...
October 15, 2018: Scientific Reports
Robinson Ramírez-Vélez, Mikel Izquierdo, Jorge Enrique Correa-Bautista, Alejandra Tordecilla-Sanders, María Correa-Rodríguez, Jacqueline Schmidt Rio-Valle, Emilio González-Jiménez, Katherine González-Ruíz
Paediatric non-alcoholic fatty liver disease (NAFLD) is considered the most common early driver of chronic liver disease. The aim of this study was to examine whether grip strength moderates the association between anthropometric and body composition parameters and controlled attenuation parameter (CAP), an indicator of fat deposits in the liver, in children and adolescents with excess of adiposity. A total of 127 adolescents (67% girls) aged between 11 and 17, attending two public schools in Bogotá (Colombia), who had an axiological evaluation of obesity were included in this study...
October 12, 2018: Journal of Clinical Medicine
Lisa L Koorneef, José K van den Heuvel, Jan Kroon, Mariëtte R Boon, Peter A C 't Hoen, Kristina M Hettne, Nienke M van de Velde, Kelsey B Kolenbrander, Trea C M Streefland, Isabel M Mol, Hetty C M Sips, Szymon M Kielbasa, Hailiang Mei, Joseph K Belanoff, Alberto M Pereira, Maaike H Oosterveer, Hazel Hunt, Patrick C N Rensen, Onno C Meijer
Non-alcoholic fatty liver disease (NAFLD) medication is an unmet need. Glucocorticoid stress hormones (GC) drive fat metabolism in the liver, but both full blockade and full stimulation of GC signaling aggravate NAFLD pathology. We investigated the efficacy of selective glucocorticoid receptor (GR) modulator CORT118335, that recapitulates only a subset of GC actions, in reducing liver lipid accumulation in mice. Male C57BL/6J mice received low-fat diet, or high-fat diet mixed with vehicle or CORT118335. Livers were analyzed histologically and for genome-wide mRNA expression...
October 12, 2018: Endocrinology
Junli Ma, Houkai Li
In recent years, accumulating evidence has indicated the importance of gut microbiota in maintaining human health. Gut dysbiosis is associated with the pathogenesis of a number of metabolic diseases including obesity, type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and cardiovascular diseases (CVDs). Indeed, CVD has become the leading cause of death worldwide, especially in developed countries. In this review, we mainly discuss the gut microbiota-involved mechanisms of CVD focusing on atherosclerosis and hypertension, two major risk factors for serious CVD...
2018: Frontiers in Pharmacology
J G Abraldes, J Trebicka, N Chalasani, G D'Amico, D Rockey, V Shah, J Bosch, G Garcia-Tsao
Portal hypertension is the main driver of cirrhosis decompensation, the main determinant of death in patients with cirrhosis. Portal hypertension results initially from increased intrahepatic vascular resistance. Later, increased inflow from splanchnic vasodilation and increased cardiac output lead to a further increase in portal pressure. Reducing portal pressure in cirrhosis results in better outcomes. Removing the cause of cirrhosis might improve portal pressure. However, this is a slow process and patients may continue to be at risk of decompensation...
October 15, 2018: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"